Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences (Nasdaq: RNA) said management will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference in New York on Oct 21, 2025 at 11:00 a.m. PT / 2:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avidity Biosciences (Nasdaq: RNA) said management will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference in New York on Oct 21, 2025 at 11:00 a.m. PT / 2:00 p.m. ET. A live webcast, event details, and an archived replay will be available on the company's Investors > Events and Presentations webpage.
This is a scheduled investor-conference panel appearance; no financial or clinical data, guidance, or transactions were announced.
Details
News Market Reaction – RNA
On Oct 16, the day this news came out, RNA closed 3.35% below the previous close.
Data tracked by StockTitan Argus for the Oct 16 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-
Chardan 9th Annual Genetic Medicines Conference,
New York, NY
Tuesday, October 21, 2025, at 11:00 a.m. PT / 2:00 p.m. ET
A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
Media Contact:
Kristina Coppola
(619) 837-5016
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302585667.html
SOURCE Avidity Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.